Orgenesis

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment, through MaSTherCell, consists of services from cell therapy development through cell therapy manufacturing and companies that provide an end-to-end solution. The POC segment provides a multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Reports Progress in Advancing the Rollout of the POCare Platform  and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc.

Orgenesis Provides Business Update for Second Quarter of 2023

GERMANTOWN, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 11, 2023, to discuss the company's corporate progress and other developments.

Orgenesis Schedules Second Quarter 2023 Business Update Conference Call

GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced the appointment of Elliot Maltz as Chief Financial Officer, effective September 1, 2023. Mr. Maltz succeeds Mr. Neil Reithinger, who is resigning following years of dedicated service and will remain with the Company until he completes his transition of duties, through September 1, 2023.

Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

GERMANTOWN, Md. and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and University of California, Davis (UC Davis) , today announce an agreement to roll out proprietary Orgenesis Mobile Processing Units and Labs™ (“OMPULs™”) at medical or academic institutions within the University of California system. The partnership agreement sets out a staged approach through which Orgenesis will install and operate OMPULs™, enabling their proprietary point-of-care (“POCare”) Service Platform to manufacture therapeutics at hospitals throughout California, empowering onsite production for clinical trials like the cell and gene therapies in development at UC Davis Health's Alpha Stem Cell Clinic.

Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California

GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced that cell and gene therapy pioneer Claudia Zylberberg, PhD has been appointed as an independent board member and senior advisor of its Morgenesis LLC (“Morgenesis”) point-of-care (POCare) subsidiary. As founder, board member and former CEO of Akron Bio, Dr. Zylberberg has led Akron Bio to its leadership position among makers of cGMP-compliant ancillary materials, novel products, and tools for advanced and regenerative medicines. She is also a member of the Strategic Advisory Council for the International Society for Cell & Gene Therapy, sits on the boards for Canada's CCRM and the Standards Coordinating Body (SCB) for Regenerative Medicine, and is co-founder and board chair of ARScience Biotherapeutics, a clinical developer of immunomodulators.

Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis

Program prepares scientists to meet the accelerating demand for cell and gene therapy expertise across an industry already delivering cures for dangerous diseases Program prepares scientists to meet the accelerating demand for cell and gene therapy expertise across an industry already delivering cures for dangerous diseases

Orgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master's Program

GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced that Vered Caplan, CEO of Orgenesis, will be participating in the Benchmark Company's 3rd Annual Healthcare House Call Virtual 1x1 Conference, which will be held on Tuesday, May 23, 2023.

Orgenesis to Participate in Benchmark's 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023

GERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through its US-based point-of-care (POCare) services subsidiary, Morgenesis LLC (“Morgenesis”), has signed a collaboration agreement with SCTbio, a full-service contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors. The goal of the collaboration is to open new point-of-care (POCare) sites within the Czech Republic and leverage SCTbio's GMP facility for the production of lentivirus vectors to support Morgenesis' POCare worldwide customers, including use in CAR-T cell and gene therapies (CGTs).

Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors

GERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023.

Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare Strategy

GERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and Metalmark Capital Partners (“Metalmark”), a leading private equity firm with extensive expertise in the healthcare sector, today announced that Metalmark has agreed to make an additional growth investment of $5 million into Orgenesis' US-based point-of-care (POCare) services subsidiary, Morgenesis LLC (“Morgenesis”). This investment follows the previously announced investment of $30 million in November 2022. In addition, Metalmark has committed to investing up to an additional $15 million, subject to the achievement of certain milestones.

Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service Subsidiary

Orgenesis Inc. (NASDAQ:ORGS ) Q4 2022 Earnings Conference Call March 21, 2023 11:00 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company William Jordan - TSA Investment Steve Waite - Gilder Publishing Operator Greetings. Welcome to the Orgenesis 2022 Year End Business Update Conference Call.

Orgenesis Inc. (ORGS) Q4 2022 Earnings Call Transcript

Rapid g rowth r eflect s p rogress of POCare Platform

Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022

GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, March 21, 2023, to discuss the company's corporate progress and other developments.

Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call

GERMANTOWN, Md., March 16, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announces the signing of a non-binding memorandum of understanding (MOU) with University of California, Davis (UC Davis).

Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California

GERMANTOWN, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced the closing of its previously announced Registered Direct Offering of 1,947,368 common stock and warrants to purchase up to 973,684 shares of common stock at a purchase price of $1.90 per share of common stock and accompanying warrants in a registered direct offering. The completion of the transaction has resulted in aggregate gross proceeds to the Company of approximately $3.7 million before deducting the placement agent's fees and other offering expenses payable by the Company. The warrants have an exercise price of $1.90 per share, are exercisable immediately and will expire five years following the date of issuance.

Orgenesis Inc. Announces Closing of $3.7 Million Registered Direct Offering

GERMANTOWN, Md., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,947,368 common stock and warrants to purchase up to 973,684 shares of common stock at a purchase price of $1.90 per share of common stock and accompanying warrants in a registered direct offering. The aggregate gross proceeds to the Company are expected to be approximately $3.7 million before deducting the placement agent's fees and other offering expenses payable by the Company. The warrants have an exercise price of $1.90 per share, are exercisable immediately and will expire five years following the date of issuance. The warrants have an alternate cashless option (beginning on or after the earlier of (a) the thirty-day anniversary of the date of the purchase agreement and (b) the date on which the aggregate composite trading volume of our common stock following the public announcement of the pricing terms exceeds 13,600,000 shares), to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise and (y) 1.0.

Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering

Fintel reports that New Dimensions Trading has filed a 13G form with the SEC disclosing ownership of 1,370,000 shares of Orgenesis Inc (ORGS).

New Dimensions Trading Discloses Large Position in ORGS / Orgenesis

Orgenesis (NASDAQ:ORGS ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Orgenesis Third Quarter 2022 Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Mr.

Orgenesis (ORGS) Q3 2022 Earnings Call Transcript

Secures up to $50 Million of Funding from Metalmark Capital Partners  Expected to Accelerate Rollout of Point-of-Care Services

Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022

GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, November 11, 2022 to discuss the company's corporate progress and other developments.

Orgenesis Schedules Third Quarter 2022 Business Update Conference Call

GERMANTOWN, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and Metalmark Capital Partners (“Metalmark”), a leading private equity firm with extensive expertise in the healthcare sector, today announced an investment partnership whereby Metalmark has agreed to make a growth investment of up to $50 million in Orgenesis' US-based point of care services subsidiary, Morgenesis LLC (“Morgenesis”). The investment will be made at a pre-money valuation of $125 million, subject to customary adjustments, and will consist of an upfront investment of $30 million and two future investments of $10 million each, subject to the achievement of certain milestones. The initial investment of $30 million will consist of $20 million in cash and conversion of the convertible loan Metalmark previously provided to Morgenesis in August 2022.

Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services

Orgenesis, Inc. (NASDAQ:ORGS ) Q2 2022 Earnings Conference Call August 16, 2022 11:00 AM ET Company Participants David Waldman – Investor Relations Vered Caplan – Chief Executive Officer Neil Reithinger – Chief Financial Officer Conference Call Participants Bruce Jackson – The Benchmark Company Operator Good day, ladies and gentlemen, and welcome to the Orgenesis Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, David Waldman from Investor Relations.

Orgenesis, Inc's (ORGS) CEO Vered Caplan on Q2 2022 Results - Earnings Call Transcript

Orgenesis (NASDAQ:ORGS) Inc announced second-quarter 2022 revenue of $7.2 million and provided a business update for the period ending June 30, 2022. The global biotech company also said it secured a $10 million loan from investment firm Metalmark Capital Partners for Orgenesis (NASDAQ:ORGS)' point of care (POCare) services business for treating patients.

Orgenesis sees 2Q revenue of $7.2M; eyes future sales from POCare platform

Secures Funding from Metalmark Capital Partners to Drive Growth

Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022

GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, August 16, 2022 to discuss the company's corporate progress and other developments.

News for Orgenesis Stock (ORGS)